We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




CRC Gut Microbial Signatures Lead to Diagnostic Tests

By LabMedica International staff writers
Posted on 18 Apr 2019
Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). More...
A cancer is the abnormal growth of cells that have the ability to invade or spread to other parts of the body.

Meta-analyses of metagenomic data are spelling out some of the roles that gut microbes play in CRC) and are suggesting new biomarkers for diagnostic and prognostic tests. Association studies have linked microbiome alterations with many human diseases. However, they have not always reported consistent results, thereby necessitating cross-study comparisons.

A team of international scientists collaborating with the University of Trento (Trento, Italy) elsewhere combined metagenomic data for 624 fecal samples from CRC patients and controls that were sequenced for five past studies and data from 140 newly-sequenced samples from two new cohorts. In the CRC samples, their analysis revealed gut microbial community enrichment and an increase in species typically linked to the oral microbiome, results they verified using data for two more cohorts comprised of 100 CRC cases and 105 controls.

The team focused on the specific microbial pathways that were over- or underrepresented in the CRC cases, and they observed an apparent rise in choline metabolism and enhanced activity by gluconeogenesis, putrefaction, and fermentation pathways. Compared to unaffected control individuals, the cases also appeared to have gut microbial communities with less active starch degradation and stachyose pathways. They also used the data to come up with a microbiome-based signature for distinguishing between individuals with or without CRC, including microbes such as Fusobacterium nucleatum, which has been implicated in CRC in the past. Pooled analysis of raw metagenomes showed that the choline trimethylamine-lyase gene was overabundant in CRC, identifying a relationship between microbiome choline metabolism and CRC.

The authors concluded that the combined analysis of heterogeneous CRC cohorts thus identified reproducible microbiome biomarkers and accurate disease-predictive models that can form the basis for clinical prognostic tests and hypothesis-driven mechanistic studies. Nicola Segata, PhD, an assistant professor and co-senior author of the study, said, “We not only established a panel of gut microbes associated with colorectal cancer across populations, but also found signatures in microbial metabolism that have similar predictive power. These will enable new studies aiming at understanding how gut microbes may contribute causally to cancer development. The study was published on April 1, 2019, in the journal Nature Medicine.

Related Links:
University of Trento


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Drug Test Kit
DrugCheck 3000
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.